Moberg Pharma Valuation Multiples

Moberg Pharma Overview

About Moberg Pharma

Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company’s main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Founded

2006

HQ

Employees

9

Website

mobergpharma.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($3M)

EV

$29M

Valuation Multiples

Multiples.vc

Start free trial

Moberg Pharma Financials

Moberg Pharma reported last 12-month revenue of $2M and negative EBITDA of ($3M).

In the same LTM period, Moberg Pharma generated $1M in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).

Moberg Pharma P&L

In the most recent fiscal year, Moberg Pharma reported revenue of $2M and EBITDA of ($2M).

Moberg Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Moberg Pharma Stock Performance

Moberg Pharma has current market cap of $54M, and enterprise value of $29M.

Moberg Pharma's stock price is $1.15.

Moberg Pharma Valuation Multiples

Moberg Pharma trades at 16.0x EV/Revenue multiple, and (10.8x) EV/EBITDA.

Moberg Pharma Financial Valuation Multiples

As of April 18, 2026, Moberg Pharma has market cap of $54M and EV of $29M.

Equity research analysts estimate Moberg Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Moberg Pharma has a P/E ratio of (19.0x).

Moberg Pharma Margins & Growth Rates

Moberg Pharma's revenue in the last 12 month grew by 99%.

Moberg Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

Moberg Pharma's rule of 40 is (18%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Moberg Pharma's rule of X is 91% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Moberg Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Moberg Pharma M&A Activity

Moberg Pharma acquired XXX companies to date.

Last acquisition by Moberg Pharma was on XXXXXXXX, XXXXX. Moberg Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Moberg Pharma Investment Activity

Moberg Pharma invested in XXX companies to date.

Moberg Pharma made its latest investment on XXXXXXXX, XXXXX. Moberg Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).